SG11201408619WA - Saxagliptin salts - Google Patents

Saxagliptin salts

Info

Publication number
SG11201408619WA
SG11201408619WA SG11201408619WA SG11201408619WA SG11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA SG 11201408619W A SG11201408619W A SG 11201408619WA
Authority
SG
Singapore
Prior art keywords
saxagliptin
international
delhi
singh
del
Prior art date
Application number
SG11201408619WA
Inventor
Ram Chander Aryan
Ashwani Kumar Singh
Amit Sharma
Ramendra Singh Rathore
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of SG11201408619WA publication Critical patent/SG11201408619WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 9 January 2014 (09.01.2014) WIPOIPCT (10) International Publication Number WO 2014/006569 A2 (51) International Patent Classification: C07D 209/52 (2006.01) (21) International Application Number: PCT/IB2013/055429 2 July 2013 (02.07.2013) (22) International Filing Date: (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2061/DEL/2012 2 July 2012 (02.07.2012) IN 3917/DEL/2012 19 December 2012 (19.12.2012) IN (71) Applicant: RANBAXY LABORATORIES LIMITED [IN/IN]; Head Office: 12th Floor, Devika Tower, 06 Nehru Place, New Delhi, Delhi 110019 (IN). (72) Inventors: ARYAN, Ram, Chander; 1066, Sector-A, Pocket-A, Vasant Kunj, New Delhi, Delhi 110070 (IN). SINGH, Ashwani, Kumar; Opposite Post Office, Main Road, Khemganj, Sirsaganj, Firozabad, Uttar Pradesh 205151 (IN). SHARMA, Amit; House No. 108/B-l, Mod­ el Town, Pinjore, Panchkula, Haryana 134102 (IN). RATHORE, Ramendra, Singh; House No. 4/1, Mohalla, Chobdaran, Farrukhabad, Uttar Pradesh 209625 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ as o o o CJ (54) Title: SAXAGLIPTIN SALTS (57) Abstract: The present invention provides saxagliptin bisulphate, saxagliptin acetate, saxagliptin oxalate, saxagliptin bicarbon­ ate, and saxagliptin carbonate, their polymorphic forms, processes for their preparation, and pharmaceutical compositions thereof.
SG11201408619WA 2012-07-02 2013-07-02 Saxagliptin salts SG11201408619WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2061DE2012 2012-07-02
IN3917DE2012 2012-12-19
PCT/IB2013/055429 WO2014006569A2 (en) 2012-07-02 2013-07-02 Saxagliptin salts

Publications (1)

Publication Number Publication Date
SG11201408619WA true SG11201408619WA (en) 2015-01-29

Family

ID=54193750

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408619WA SG11201408619WA (en) 2012-07-02 2013-07-02 Saxagliptin salts

Country Status (5)

Country Link
EP (1) EP2867206A2 (en)
AU (1) AU2013285078A1 (en)
CA (1) CA2879824A1 (en)
SG (1) SG11201408619WA (en)
WO (1) WO2014006569A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013175297A1 (en) 2012-05-24 2013-11-28 Apotex Pharmachem India Pvt. Ltd Salts of saxagliptin with organic acids
WO2015166466A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Crystalline form of saxagliptin acetate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor
PE20090696A1 (en) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
CN102459170B (en) 2009-04-09 2014-07-23 桑多斯股份公司 Crystal forms of saxagliptin
EP2601175A1 (en) 2010-08-06 2013-06-12 Sandoz AG A novel crystalline compound comprising saxagliptin and phosphoric acid
WO2012017029A1 (en) * 2010-08-06 2012-02-09 Sandoz Ag Novel salts of saxagrliptin with organic di-acids
US8410288B2 (en) 2010-10-04 2013-04-02 Teva Pharmaceutical Industries Ltd. Polymorphs of Saxagliptin hydrochloride and processes for preparing them
CN102086172A (en) * 2011-01-13 2011-06-08 廖国超 Medicinal salts of saxagliptin and preparation methods of medicinal salts

Also Published As

Publication number Publication date
WO2014006569A2 (en) 2014-01-09
EP2867206A2 (en) 2015-05-06
CA2879824A1 (en) 2014-01-09
AU2013285078A1 (en) 2015-01-29
WO2014006569A3 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201408261UA (en) Syringe
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201408739VA (en) Inhibitors of hepatitis c virus
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201408094YA (en) Neprilysin inhibitors
SG11201407533SA (en) Antiviral compounds
SG11201804811WA (en) Fenfluramine compositions and methods of preparing the same
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201900545TA (en) Pharmaceutical compounds
SG11201407988UA (en) Process for improved opioid synthesis
SG11201407934UA (en) Camsylate salt
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
SG11201407319YA (en) Compositions and methods for treatment of inflammatory bowel disease